1 / 14

Swedish-American Life Science Summit 2008

Swedish-American Life Science Summit 2008. Biotech under Dire Conditions Aug 20, 2008 Thomas von Koch . EQT today: Northern European private equity fund with local knowledge. Stockholm 12 Partners 18 Other Professionals. Oslo 1 Partner 2 Other Professionals. New York 1 Partners

wattan
Download Presentation

Swedish-American Life Science Summit 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Swedish-American Life Science Summit 2008 Biotech under Dire Conditions Aug 20, 2008 Thomas von Koch

  2. EQT today: Northern European private equity fund with local knowledge Stockholm 12 Partners 18 Other Professionals Oslo 1 Partner 2 Other Professionals New York 1 Partners 3 Other Professionals • Entrepreneurs with an industrial orientation and a strong will to drive change • Part of the Wallenberg network • Strong record of delivering superior returns to investors over time • Founded in 1994, over €12Bn in capital raised • 3 business lines • Buy-out in Europe and Greater China • Mezzanine • Special Opportunities • 178 people • 13 offices Helsinki 1 Partner 6 Other Professionals Copenhagen 3 Partners 5 Other Professionals Frankfurt 2 Partners 5 Other Professionals Zurich 1 Partner Munich 7 Partners 14 Other Professionals Shanghai 3 Professionals Hong Kong 2 Partners 7 Other Professionals

  3. 5% Approx. 30 divestments (1997 – 2008) Analysis of value creation in all EQT Equity’s exits • % of equity created Value Driver Sales growth 32% Margin expansion Strategic re-positioning 17% Debt pay down Label

  4. Proof of industrial model Yearly growth during ownership period in all investments held more than 1 year EBITDA 20% Number of employees 12% Sales 13%

  5. Opportunities exist across segments, so far EQT has made acquisitions in Medtech mainly Pharmaceuticals Medtech* Service providers Large cap pharma Niche pharma Biotech Diagnostic & Monitoring PI&D, Consumables & Supplies Primary Acute care Post- sub-acute care B2B healthcare services (& intermediaries) Healthcare IT CXOs Product distribution Physician Practice Mgmt Disease Management Other

  6. Private Equity fundraising still strong – albeit slowing down USD (Billion) BO = 90% BO = 64% Source: US Data: Private Equity Analyst, Europe Data: EVCA Does not include Real Estate or Fund of Funds

  7. Fundraising – Dire Future • Asset Managers over-allocated to PE • PE Managers performance rapidly deteriorating • Risk/ Reward for asset class in current market not appealing PE Fund Managers will hold on to their money

  8. Current financing situation- deal volume and deal count Volume (in €bn) Deal count Q4 Q3 Q2 Q1 Deal count 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Source: Thomson Financial, JP Morgan

  9. Debt Market Closed • 300 Bn USD of LBO debt “stuck” in banks’ balance sheets • All LBO debt trading below nominal value • London/ NY bank syndication markets closed – uncertain when/ if they will open • Very hard to make transactions in excess of 1 Bn Euro Very few LBO transactions will be made

  10. Deal Activity Collapsing • Not a functioning debt market • No exit market available • IPO closed • PE semi-closed • Industrial buyers window closing • Business cycle in decline

  11. During last 18 months 24 major PE deals have been made in European healthcare COMPANY BUYER YEAR REGION DEAL SIZE (€M) MEDTECH* HEALTHCARE PROVIDERS PHARMA, BIOTECH & OTHER HEALTHCARE Note: * Medtech includes medical devices and supplies; Includes all LBO transactions involving European targets valued >$75M by European- and foreign-based firms Source: Bain European Private Equity database

  12. Risk Aversion – where will the money go? • Private market almost closed • Buy out liquidity low/ Venture Capital worse • Trend of PE money becoming public activist money • Trend of PE money becoming debt oriented money. Todayequity returns for taking junior debt risk

  13. Concluding remarks • Risk aversion at a high point • Nuclear melt down in financial markets must be resolved • Negative business cycle sentiment must turn • Only positive Healthcare is a defensive sector It will take time until Private Equity is back to normal

More Related